中东和非洲基因检测市场，按类型（携带者检测、诊断检测、新生儿筛查、预测性和症状前检测、产前检测、其他类型）、技术（DNA 测序（基于 NGS 的检测）、聚合酶链反应、微阵列、全基因组测序、荧光原位杂交 (FISH) 等）、疾病（罕见遗传病、癌症、囊性纤维化、生殖基因检测、健康与保健基因检测、镰状细胞性贫血、杜氏肌营养不良症、地中海贫血、亨廷顿氏病、脆性 X 综合征等）、最终用户（医院、诊所、诊断中心、私人诊所、实验室服务提供商和私人实验室）行业趋势和预测到 2030 年。
中东和非洲基因检测市场分析和见解
中东和非洲基因检测市场受到诸多因素的推动，例如遗传疾病的患病率高、基因检测市场技术进步不断提高（这增加了其需求）以及研发投资不断增加（这导致市场增长）。目前，发达国家和新兴国家的医疗保健支出都有所增加，这有望为制造商创造竞争优势，以开发新的创新基因检测市场。
中东和非洲基因检测市场预计将在 2023 年至 2030 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在 2023 年至 2030 年的预测期内，该市场的复合年增长率为 13.6%，预计到 2030 年将达到 13.7413 亿美元。
中东和非洲基因检测市场报告提供了市场份额、新发展和产品线分析的详细信息，国内和本地化市场参与者的影响，分析了新兴收入领域、市场法规变化、产品批准、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情况，请联系我们获取分析师简报，我们的团队将帮助您创建收入影响解决方案，以实现您的期望目标。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制至 2020-2015) |
|
定量单位 |
收入（百万美元） |
|
涵盖的领域 |
按类型（携带者检测、诊断检测、新生儿筛查、预测性和症状前检测、产前检测、其他类型）、技术（DNA测序（基于NGS的检测）、聚合酶链式反应、微阵列、全基因组测序、荧光原位杂交（FISH）等）、疾病（罕见遗传病、癌症、囊性纤维化、生殖基因检测、健康与保健基因检测、镰状细胞性贫血、杜氏肌营养不良症、地中海贫血、亨廷顿氏病、脆性X综合征等）、最终用户（医院、诊所、诊断中心、私人诊所、实验室服务提供商和私人实验室）。 |
|
覆盖国家 |
南非、沙特阿拉伯、阿联酋、埃及、以色列、中东其他地区和非洲。 |
|
涵盖的市场参与者 |
雅培、23ANDME, Inc.、丹纳赫、Myriad Genetics, Inc.、OCP Medical Centre, LLC、Healthchecks360、拜耳股份公司、BioReference Health, LLC（OPKO Health, Inc. 的子公司）、FREIBURG MEDICAL LABORATORY MIDDLE EAST (LLC)、赛默飞世尔科技公司、Bio-Rad Laboratories, Inc.、Biocartis、Eurofins Scientific、PerkinElmer Inc.、ELITechGroup、F. Hoffmann-La Roche Ltd.、Illumina, Inc.、QIAGEN、BIO-HELIX 和 PacBio 等。 |
市场定义
基因检测是一种识别基因、染色体或蛋白质变化的医学测试。基因检测的结果可以确认或排除疑似遗传疾病，或帮助确定一个人患上或遗传某种遗传疾病的几率。目前有超过 77,000 种基因检测正在使用中，其他检测方法正在开发中。
不断增长的创新技术、市场参与者数量以及新产品的推出也推动了中东和非洲基因检测市场的增长。
中东和非洲基因检测市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：
驱动因素/机遇
- 遗传疾病患病率不断上升
遗传性疾病可能导致与生命不相容的严重健康问题。在最严重的情况下，这些疾病可能会导致受影响的胚胎或胎儿流产。遗传疾病和出生缺陷的患病率不断上升，推动了对基因检测市场的需求。
- 根据世界卫生组织的文章《遗传性疾病和先天畸形：减轻该地区负担的策略》（2022 年），遗传性疾病和先天性疾病占该地区许多国家围产期和新生儿死亡的很大一部分。出生缺陷现在被认为是阿拉伯联合酋长国婴儿死亡的主要原因，也是巴林、科威特、阿曼和卡塔尔的第二大原因。来自沙特阿拉伯的报告表明，两家医院约 25-35% 的产前死亡是由于出生缺陷造成的。
因此，这增加了基因检测市场的需求。
- 下一代测序的采用率提高
随着以基因组学为重点的药理学在各种慢性疾病（尤其是癌症）的治疗中发挥着越来越重要的作用，下一代测序（NGS）正在发展成为一种强有力的工具，可以更深入、更精确地了解个体肿瘤和特定受体的分子基础。
与传统方法相比，NGS 在准确性、灵敏度和速度方面具有优势，有望对肿瘤学领域产生重大影响。由于 NGS 可以在一次检测中评估多个基因，因此无需进行多次检测来确定致病突变。
因此，这有望成为基因检测市场增长的推动力。
- 可支配收入增加
一个国家在医疗保健方面的支出及其随时间的增长速度受到各种经济和社会因素的影响，包括医疗系统的融资安排和组织结构。特别是，一个国家的整体收入水平与该国人口在医疗保健方面的支出之间存在很强的相关性。
此外，主要市场参与者采取的战略举措将为 2023-2030 年预测期内的基因检测市场提供结构完整性和未来机会。
限制/挑战
- 基因检测费用高昂
基因检测费用昂贵，而且有些健康保险计划可能不予报销。多种基因检测的费用因检测的目标疾病而异。
- 根据Breastcancer.org的数据，癌症基因检测的费用差异很大，可能在300美元到5000美元之间。基因检测的费用取决于检测类型以及检测的复杂程度
- 基因检测的费用从 100 美元到 2,000 美元不等，具体取决于检测的性质和复杂程度。如果需要进行多项检测或必须对多名家庭成员进行检测才能获得有意义的结果，费用就会增加。新生儿筛查的费用因州而异
因此，基因检测的高成本可能会抑制市场的增长。
- 严格的监管政策
监管事务 (RA) 在医疗器械行业中发挥着至关重要的作用，因为它与医疗保健产品的生命周期息息相关。它服务于战术、战略和运营路径，并协助在法规范围内运作，以加快向全球人口提供和开发安全有效的癌症唾液测试设备和产品。监管事务的作用是制定和执行监管战略。
许多医疗机构和政府机构都在为癌症唾液检测设备和产品的上市和审批提供监管政策。产品获得区域监管机构的批准对药物开发团队来说至关重要。该批准确保了公司的药物开发活动，并使公司在竞争中脱颖而出。
后新冠疫情对中东和非洲基因检测市场的影响
基因检测市场受到 COVID-19 的严重影响。疫情期间，医院入院人数仅限于非必要治疗，诊所也暂时关闭。社交距离的实施、人群封锁和诊所准入限制极大地影响了市场。患者流量和转诊的放缓也影响了市场的增长。然而，由于先前实施的限制措施有所放松，市场将在疫情后继续增长。
制造商正在制定各种战略决策，以在新冠疫情后实现复苏。参与者正在进行多项研发活动和产品发布，并建立战略合作伙伴关系，以改进基因检测市场所涉及的技术和检测结果。
近期发展
- 2022 年 11 月 10 日，基因检测和精准医疗领域的领导者 Myriad Genetics, Inc. 宣布推出 UroSuite，这是一套全面的遗传风险评估测试，涵盖前列腺癌护理的所有阶段。UroSuite 包括 Myriad 的 Prolaris 前列腺癌测试、MyRisk 遗传性癌症测试、BRACAnalysis CDx 和 Precise 肿瘤分子谱测试。这些测试的组合提供了综合的遗传概述，并有助于患者治疗和选择临床试验。
- 2022 年 9 月，DNA 测序和基于阵列的技术的全球领导者 Illumina, Inc. 宣布推出 NovaSeq X 系列（NovaSeq X 和 NovaSeq X Plus）。这些是新的生产规模测序仪，通过实现更快、更高效和更可持续的测序，突破了基因组医学的界限。凭借革命性的新技术，NovaSeq X Plus 每年可以生成超过 20,000 个全基因组——性能是以前测序仪的 2.5 倍——大大加速了基因组发现和临床洞察，以了解疾病并最终改变患者的生活。
中东和非洲基因检测市场范围
中东和非洲基因检测市场分为类型、技术、疾病和最终用户。这些细分市场之间的增长将帮助您分析和衡量行业中的增长细分市场，并为用户提供有价值的市场概览和市场洞察，以做出战略决策，确定核心市场应用。
类型
- 诊断测试
- 产前检查
- 新生儿筛查
- 预测性和症状前检测
- 携带者检测
- 其他类型
根据类型，中东和非洲基因检测市场分为诊断检测、产前检测、新生儿筛查、预测和症状前检测、携带者检测等类型。
技术
- 聚合酶链反应
- DNA 测序（基于 NGS 的测试）
- 全基因组测序
- 微阵列
- 荧光原位杂交（FISH）
- 其他的
根据技术，中东和非洲基因检测市场分为 DNA 测序、聚合酶链反应、微阵列、全基因组测序、荧光原位杂交 (FISH) 等。
疾病
- 癌症
- 镰状细胞性贫血
- 地中海贫血
- 罕见遗传病
- 脆性 X 综合征
- 杜氏肌营养不良症
- 亨廷顿氏病
- 囊性纤维化
- 生殖基因检测
- 健康与保健基因检测
- 其他的
根据疾病，中东和非洲基因检测市场细分为罕见遗传病、癌症、囊性纤维化、镰状细胞性贫血、杜氏肌营养不良症、地中海贫血、亨廷顿氏病、脆性 X 综合征、生殖基因检测、健康与保健基因检测等。
最终用户
- 医院
- 诊所
- 诊断中心
- 私人诊所
- 实验室服务提供商
- 私人实验室
根据最终用户，中东和非洲基因检测市场分为医院、诊所、诊断中心、私人诊所、实验室服务提供商和私人实验室。
中东和非洲基因检测市场区域分析/见解
对中东和非洲的基因检测市场进行了分析，并按类型、技术、疾病和最终用户提供了市场规模信息。
本市场报告涵盖的国家包括南非、沙特阿拉伯、阿联酋、埃及、以色列、中东和非洲其他国家。
2023 年，南非预计将占据主导地位，因为增加对研发的投资预计将推动市场增长。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了中东和非洲品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战以及销售渠道的影响。
竞争格局和中东和非洲基因检测市场份额分析
中东和非洲基因检测市场竞争格局提供竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用主导地位、技术生命线曲线。以上提供的数据点仅与公司对中东和非洲基因检测市场的关注有关。
中东和非洲基因检测市场的一些主要参与者包括雅培、23ANDME, Inc.、丹纳赫、Myriad Genetics, Inc.、OCP Medical Centre, LLC、Healthchecks360、拜耳股份公司、BioReference Health, LLC（OPKO Health, Inc. 的子公司）、FREIBURG MEDICAL LABORATORY MIDDLE EAST (LLC)、赛默飞世尔科技、Bio-Rad Laboratories, Inc.、Biocartis、Eurofins Scientific、PerkinElmer Inc.、ELITechGroup、F. Hoffmann-La Roche Ltd.、Illumina, Inc.、QIAGEN、BIO-HELIX 和 PacBio 等。
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、中东和非洲与地区以及供应商份额分析。如有进一步询问，请要求分析师致电。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA GENETIC TESTING MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 YEARS CONSIDERED FOR THE STUDY
2.3 CURRENCY AND PRICING
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 MULTIVARIATE MODELLING
2.6 TYPE LIFELINE CURVE
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET APPLICATION COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL’S MODEL
4.2 PORTER'S FIVE FORCES MODEL
4.3 STRATEGIC INITIATIVES:
5 INDUSTRY INSIGHTS
5.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
5.2 CANCER GENETICS RISK ASSESSMENT AND COUNSELING
5.3 GENETIC TESTS PRICING AND KEY PRICING STRATEGIES
5.3.1 LAUNCH OF NEW TECHNOLOGY GENETIC TESTING KITS
5.3.2 PARTNERSHIPS WITH MARKET PLAYERS
5.3.3 PRENATAL PRICING STRATEGY
5.4 KEY PATIENT ENROLLMENT STRATEGIES
5.4.1 AWARENESS OF THE PUBLIC TOWARDS GENETIC TESTING TECHNOLOGY
5.4.2 GENETIC COUNSELLORS' SCOPE OF PRACTICE
5.4.3 EDUCATION AND COMMUNICATION
6 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: REGULATIONS
7 EPIDEMIOLOGY
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 GROWING PREVALENCE OF GENETIC DISORDERS
8.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING
8.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY MAJOR PLAYER
8.1.4 INCREASE TREND TOWARD PERSONALIZED MEDICATION
8.2 RESTRAINT
8.2.1 HIGH COST OF GENETIC TESTING
8.2.2 CYBER SECURITY CONCERN IN GENOMICS
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER
8.3.2 TECHNOLOGICAL ADVANCEMENTS IN GENETIC TESTING
8.3.3 INCREASING RESEARCH AND DEVELOPMENT
8.3.4 RISING DISPOSABLE INCOME
8.4 CHALLENGES
8.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM GENETIC TESTING
8.4.2 STRINGENT REGULATION POLICY
9 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY TYPE
9.1 OVERVIEW
9.2 DIAGNOSTIC TESTING
9.3 PRENATAL TESTING
9.3.1 NON-INVASIVE SCREENING
9.3.1.1 BY SCREENING METHOD
9.3.1.1.1 WHOLE GENOME SEQUENCING
9.3.1.1.2 COUNTING OF CFDNA FRAGMENTS
9.3.1.1.3 OTHERS
9.3.1.2 BY CONDITION
9.3.1.2.1 TRISOMY 21
9.3.1.2.2 KLINEFELTER SYNDROME
9.3.1.2.3 JACOBS SYNDROME
9.3.1.2.4 CYSTIC FIBROSIS
9.3.1.2.5 TURNER SYNDROME
9.3.1.2.6 TRISOMY 18
9.3.1.2.7 HEMOPHILIA
9.3.1.2.8 TRISOMY 13
9.3.1.2.9 MICRODELETION SYNDROME
9.3.1.2.10 FETAL GENDER
9.3.1.2.11 OTHERS
9.3.1.3 BY SCREENING TYPE
9.3.1.3.1 CARRIER SEQUENCING
9.3.1.3.2 SEQUENTIAL SEQUENCING
9.3.2 MATERNAL SERUM QUAD SCREENING
9.4 NEW BORN SCREENING
9.4.1 SICKLE CELL DISEASE
9.4.2 CONGENITAL HYPOTHYROIDISM
9.4.3 PHENYLKETONURINA (PKU)
9.4.4 GALACTOSEMIA
9.4.5 MAPLE SYRUP URINE DISEASE
9.4.6 OTHERS
9.5 PREDICTIVE AND PRESYMPTOMATIC TESTING
9.6 CARRIER TESTING
9.6.1 BY TEST TYPE
9.6.1.1 MOLECULAR SCREENING TEST
9.6.1.2 BIOCHEMICAL SCREENING TEST
9.6.2 BY TYPE
9.6.2.1 EXPANDED CARRIER SCREENING
9.6.2.1.1 PREDESIGNED PANEL TESTING
9.6.2.1.2 CUSTOM-MADE PANEL TESTING
9.6.2.2 TARGETED DISEASE CARRIER SCREENING
9.6.3 BY MEDICAL CONDITION
9.6.3.1 HEMATOLOGICAL CONDITIONS
9.6.3.2 PULMONARY CONDITIONS
9.6.3.3 NEUROLOGICAL CONDITIONS
9.6.3.4 OTHER CONDITIONS
9.7 OTHER TYPES
10 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY TECHNOLOGY
10.1 OVERVIEW
10.2 POLYMERASE CHAIN REACTION
10.2.1 REAL-TIME PCR (QPCR)
10.2.2 DIGITAL PCR (DPCR)
10.2.3 REVERSE TRANSCRIPTION PCR (RT-PCR)
10.2.4 HOT-START PCR
10.2.5 MULTIPLEX PCR
10.2.6 OTHER PCR
10.3 DNA SEQUENCING (NGS-BASED TESTING)
10.3.1 NEXT GENERATION SEQUENCING (NGS)
10.3.2 SANGER SEQUENCING (SINGLE GENE)
10.3.3 OTHER
10.4 WHOLE GENOME SEQUENCING
10.5 MICROARRAYS
10.5.1 DNA MICROARRAYS
10.5.2 PROTEIN MICROARRAYS
10.5.3 OTHER MICROARRAYS
10.6 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
10.7 OTHERS
11 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY DISEASES
11.1 OVERVIEW
11.2 CANCER
11.2.1 BREAST
11.2.2 COLON
11.2.3 LUNG
11.2.4 PROSTATE
11.2.5 OTHERS
11.3 REPRODUCTIVE GENETIC TESTING
11.4 HEALTH AND WELLNESS GENETIC TESTING
11.5 SICKLE CELL ANEMIA
11.6 THALASSEMIA
11.7 RARE GENETIC DISORDER
11.7.1 TRISOMY 21
11.7.2 MONOSOMY X
11.7.3 TRISOMY 13
11.7.4 MICRODELETION SYNDROME
11.7.5 TRISOMY 18
11.7.6 OTHERS
11.8 FRAGILE X SYNDROME
11.9 DUCHENNE MUSCULAR DYSTROPHY
11.1 HUNTINGTON'S DISEASE
11.11 CYSTIC FIBROSIS
11.12 OTHERS
12 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 CLINICS
12.4 DIAGNOSTIC CENTERS
12.5 PRIVATE CLINICS
12.6 LABORATORY SERVICE PROVIDERS
12.7 PRIVATE LABORATORIES
13 SUMMARY WRITE-UP (MIDDLE EAST AND AFRICA)
13.1 OVERVIEW
13.2 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY COUNTRY
13.2.1 SOUTH AFRICA
13.2.2 SAUDI ARABIA
13.2.3 U.A.E.
13.2.4 ISRAEL
13.2.5 EGYPT
13.2.6 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 BAYER AG
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 PRODUCT PORTFOLIO
16.1.4 RECENT DEVELOPMENTS
16.2 ABBOTT
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 PRODUCT PORTFOLIO
16.2.4 RECENT DEVELOPMENTS
16.3 ILLUMINA, INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 PRODUCT PORTFOLIO
16.3.4 RECENT DEVELOPMENTS
16.4 THERMO FISHER SCIENTIFIC INC.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
16.5 F.HOFFAMANN-LA ROCHE LTD.
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENTS
16.6 BIOREFERNCE HEALTH INC. (SUBSIDIARY OPKO HEALTH, INC.)
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENTS
16.7 ELITECHGROUP
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENTS
16.8 23ANDME, INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENTS
16.9 BIOCARTIS
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENTS
16.1 BIO-HELIX
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENTS
16.11 BIO-RAD LABORATORIES, INC.
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENTS
16.12 DANAHER
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENTS
16.13 EUROFINS SCIENTIFIC
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENTS
16.14 FREIBURG MEDICAL LABORATORY MIDDLE EAST (L.L.C)
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENTS
16.15 HEALTHCHECKS360
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENTS
16.16 MYRIAD GENETICS, INC.
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENTS
16.17 OCP MEDICAL CENTER L.L.C
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENTS
16.18 PACBIO
16.18.1 COMPANY SNAPSHOT
16.18.2 REVENUE ANALYSIS
16.18.3 PRODUCT PORTFOLIO
16.18.4 RECENT DEVELOPMENTS
16.19 PERKINELMER ONC.
16.19.1 COMPANY SNAPSHOT
16.19.2 REVENUE ANALYSIS
16.19.3 PRODUCT PORTFOLIO
16.19.4 RECENT DEVELOPMENTS
16.2 QIAGEN
16.20.1 COMPANY SNAPSHOT
16.20.2 REVENUE ANALYSIS
16.20.3 PRODUCT PORTFOLIO
16.20.4 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
表格列表
TABLE 1 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 2 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 3 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 4 MIDDLE EAST AND AFRICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 6 MIDDLE EAST AND AFRICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 7 MIDDLE EAST AND AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (UNITS)
TABLE 9 MIDDLE EAST AND AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (ASP)
TABLE 10 MIDDLE EAST AND AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2021-2030 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (UNITS)
TABLE 13 MIDDLE EAST AND AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (ASP)
TABLE 14 MIDDLE EAST AND AFRICA NEW BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 17 MIDDLE EAST AND AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 18 MIDDLE EAST AND AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 20 MIDDLE EAST AND AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 21 MIDDLE EAST AND AFRICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 23 MIDDLE EAST AND AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 24 MIDDLE EAST AND AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET , BY DISEASES, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 33 IDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY COUNTRY 2021-2030 (USD MILLION)
TABLE 34 SOUTH AFRICA GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 35 SOUTH AFRICA GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 36 SOUTH AFRICA GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 37 SOUTH AFRICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 38 SOUTH AFRICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 39 SOUTH AFRICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 40 SOUTH AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (USD MILLION)
TABLE 41 SOUTH AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (UNITS)
TABLE 42 SOUTH AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (ASP)
TABLE 43 SOUTH AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2021-2030 (USD MILLION)
TABLE 44 SOUTH AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (USD MILLION)
TABLE 45 SOUTH AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (UNITS)
TABLE 46 SOUTH AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (ASP)
TABLE 47 SOUTH AFRICA NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 48 SOUTH AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 49 SOUTH AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 50 SOUTH AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 51 SOUTH AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 52 SOUTH AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 53 SOUTH AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 54 SOUTH AFRICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 55 SOUTH AFRICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 56 SOUTH AFRICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 57 SOUTH AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2021-2030 (USD MILLION)
TABLE 58 SOUTH AFRICA GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 59 SOUTH AFRICA POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 60 SOUTH AFRICA DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 61 SOUTH AFRICA MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 62 SOUTH AFRICA GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 63 SOUTH AFRICA RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 64 SOUTH AFRICA CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 65 SOUTH AFRICA GENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 66 SAUDI ARABIA GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 67 SAUDI ARABIA GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 68 SAUDI ARABIA GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 69 SAUDI ARABIA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 70 SAUDI ARABIA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 71 SAUDI ARABIA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 72 SAUDI ARABIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (USD MILLION)
TABLE 73 SAUDI ARABIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (UNITS)
TABLE 74 SAUDI ARABIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (ASP)
TABLE 75 SAUDI ARABIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2021-2030 (USD MILLION)
TABLE 76 SAUDI ARABIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (USD MILLION)
TABLE 77 SAUDI ARABIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (UNITS)
TABLE 78 SAUDI ARABIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (ASP)
TABLE 79 SAUDI ARABIA NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 80 SAUDI ARABIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 81 SAUDI ARABIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 82 SAUDI ARABIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 83 SAUDI ARABIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 84 SAUDI ARABIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 85 SAUDI ARABIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 86 SAUDI ARABIA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 87 SAUDI ARABIA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 88 SAUDI ARABIA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 89 SAUDI ARABIA CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2021-2030 (USD MILLION)
TABLE 90 SAUDI ARABIA GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 91 SAUDI ARABIA POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 92 SAUDI ARABIA DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 93 SAUDI ARABIA MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 94 SAUDI ARABIA GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 95 SAUDI ARABIA RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 96 SAUDI ARABIA CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 97 SAUDI ARABIA GENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 98 U.A.E. GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 99 U.A.E. GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 100 U.A.E. GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 101 U.A.E. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 102 U.A.E. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 103 U.A.E. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 104 U.A.E. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (USD MILLION)
TABLE 105 U.A.E. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (UNITS)
TABLE 106 U.A.E. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (ASP)
TABLE 107 U.A.E. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2021-2030 (USD MILLION)
TABLE 108 U.A.E. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (USD MILLION)
TABLE 109 U.A.E. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (UNITS)
TABLE 110 U.A.E. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (ASP)
TABLE 111 U.A.E. NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 112 U.A.E. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 113 U.A.E. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 114 U.A.E. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 115 U.A.E. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 116 U.A.E. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 117 U.A.E. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 118 U.A.E. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 119 U.A.E. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 120 U.A.E. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 121 U.A.E. CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2021-2030 (USD MILLION)
TABLE 122 U.A.E. GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 123 U.A.E. POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 124 U.A.E. DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 125 U.A.E. MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 126 U.A.E. GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 127 U.A.E. RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 128 U.A.E. CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 129 U.A.E. GENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 130 ISRAEL GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 131 ISRAEL GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 132 ISRAEL GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 133 ISRAEL PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 134 ISRAEL PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 135 ISRAEL PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 136 ISRAEL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (USD MILLION)
TABLE 137 ISRAEL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (UNITS)
TABLE 138 ISRAEL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (ASP)
TABLE 139 ISRAEL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2021-2030 (USD MILLION)
TABLE 140 ISRAEL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (USD MILLION)
TABLE 141 ISRAEL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (UNITS)
TABLE 142 ISRAEL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (ASP)
TABLE 143 ISRAEL NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 144 ISRAEL CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 145 ISRAEL CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 146 ISRAEL CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 147 ISRAEL CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 148 ISRAEL CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 149 ISRAEL CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 150 ISRAEL EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 151 ISRAEL EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 152 ISRAEL EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 153 ISRAEL CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2021-2030 (USD MILLION)
TABLE 154 ISRAEL GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 155 ISRAEL POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 156 ISRAEL DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 157 ISRAEL MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 158 ISRAEL GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 159 ISRAEL RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 160 ISRAEL CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 161 ISRAEL GENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 162 EGYPT GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 163 EGYPT GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 164 EGYPT GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 165 EGYPT PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 166 EGYPT PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 167 EGYPT PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 168 EGYPT NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (USD MILLION)
TABLE 169 EGYPT NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (UNITS)
TABLE 170 EGYPT NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (ASP)
TABLE 171 EGYPT NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2021-2030 (USD MILLION)
TABLE 172 EGYPT NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (USD MILLION)
TABLE 173 EGYPT NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (UNITS)
TABLE 174 EGYPT NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (ASP)
TABLE 175 EGYPT NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 176 EGYPT CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 177 EGYPT CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 178 EGYPT CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 179 EGYPT CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 180 EGYPT CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 181 EGYPT EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 182 EGYPT EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 183 EGYPT EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 184 EGYPT CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2021-2030 (USD MILLION)
TABLE 185 EGYPT GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 186 EGYPT POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 187 EGYPT DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 188 EGYPT MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 189 EGYPT GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 190 EGYPT RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 191 EGYPT CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 192 EGYPT GENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 193 REST OF MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
图片列表
FIGURE 1 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET:DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET :COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET : DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET : MARKET APPLICATION COVERAGE GRID
FIGURE 9 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: SEGMENTATION
FIGURE 11 THE INCREASING PREVALENCE OF GENETIC DISEASES AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA GENETIC TESTING MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 12 DIGANOSTIC TESTING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA GENETIC TESTING MARKET IN 2023 & 2030
FIGURE 13 EPIDEMIOLOGY
FIGURE 14 INCIDENCE OF ALL GENDER-SOUTH AFRICA AND SAUDI ARABIA
FIGURE 15 INCIDENCE OF ALL GENDER-UAE AND EGYPT
FIGURE 16 INCIDENCE OF ALL GENDER-ISRAEL
FIGURE 17 MORTALITY RATE- SOUTH AFRICA AND SAUDI ARABIA
FIGURE 18 MORTALITY RATE-UAE AND EGYPT
FIGURE 19 MORTALITY RATE-ISRAEL
FIGURE 20 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST AND AFRICA GENETIC TESTING MARKET
FIGURE 21 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY TYPE, 2022
FIGURE 22 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 23 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 24 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY TECHNOLOGY, 2022
FIGURE 26 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 27 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 28 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 29 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY DISEASES, 2022
FIGURE 30 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY DISEASES, 2023-2030 (USD MILLION)
FIGURE 31 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY DISEASES, CAGR (2023-2030)
FIGURE 32 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY DISEASES, LIFELINE CURVE
FIGURE 33 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY END USER, 2022
FIGURE 34 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 35 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY END USER, CAGR (2023-2030)
FIGURE 36 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: SNAPSHOT (2022)
FIGURE 38 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY COUNTRY (2022)
FIGURE 39 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY COUNTRY (2023 & 2030)
FIGURE 40 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY COUNTRY (2022 & 2030)
FIGURE 41 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY TYPE (2023-2030)
FIGURE 42 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: COMPANY SHARE 2022 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
